



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Centers for Disease Control
and Prevention (CDC)
Atlanta, GA 30341-3724

June 28, 2022

To Project PREVENT II Investigators:

We are writing to invite your site to participate in a CDC-funded public health evaluation of COVID-19 vaccine effectiveness. This effort is being harmonized across multiple CDC-funded networks, and builds on the platform set up for Project PREVENT. This evaluation is being conducted with the full support and sponsorship of the CDC's COVID-19 Response.

Healthcare personnel were identified as a group for early phase vaccination against COVID-19 when limited doses of vaccine were available. Previous evaluations of the effectiveness of COVID-19 vaccines among healthcare personnel during the early phase of vaccination, including results of the evaluations based on Project PREVENT informed adult COVID-19 vaccine policy decisions. Continued monitoring of COVID-19 vaccine effectiveness in a setting of emerging new variants is critical to inform the need for booster doses. This project is a priority for the CDC COVID-19 Response, and monitoring of COVID-19 vaccine effectiveness among healthcare personnel, a population with high adherence to current vaccine recommendations and rigorous testing, allows for early detection of waning of vaccine effectiveness in a setting of new immune escape variants or due to time elapsed since the last booster recommendations.

The project protocol has been evaluated by a CDC human subjects' advisor who determined this activity to be non-research public health surveillance. The Project PREVENT II sites will protect employee information from release. No personally identifying information will be shared with CDC.

We appreciate your expediting the review and agreement process so that you can start enrollment. This information is of critical importance to the public health response to the COVID-19 pandemic, to protect our nation's healthcare personnel, and to inform future vaccine policy decisions in the U.S.

Thank you for your efforts. We look forward to partnering with you on this important effort.

Sincerely,

A handwritten signature in black ink, appearing to read "T. Pilishvili".

Tamara Pilishvili

Lead, Vaccine Effectiveness and Policy Team
COVID-19 Response
Centers for Disease Control and Prevention